<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3263891</article-id><article-id pub-id-type="publisher-id">2035</article-id><article-id pub-id-type="doi">10.2337/dc11-2035</article-id><article-categories><subj-group subj-group-type="heading"><subject>Diabetes Care Electronic Pages</subject><subj-group><subject>Online Letters: Comments and Responses</subject></subj-group></subj-group></article-categories><title-group><article-title>Response to Comment on: Ramos-Zavala et al. Effect of Diacerein on Insulin Secretion and Metabolic Control in Drug-Na&#x000ef;ve Patients With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care 2011;34:1591&#x02013;1594</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ramos-Zavala</surname><given-names>Maria G.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-Ortiz</surname><given-names>Manuel</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Abundis</surname><given-names>Esperanza</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robles-Cervantes</surname><given-names>Jos&#x000e9; A.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname><given-names>Roberto</given-names></name><degrees>MD, MSC</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santiago-Hern&#x000e1;ndez</surname><given-names>Nestor J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup>Medical Research Unit in Clinical Epidemiology, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Institute of Social Security, Guadalajara, Mexico</aff><aff id="aff2"><sup>2</sup>Cardiovascular Research Unit, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico</aff><author-notes><corresp id="cor1">Corresponding author: Manuel Gonz&#x000e1;lez-Ortiz, <email>uiec@prodigy.net.mx</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2012</year></pub-date><volume>35</volume><issue>2</issue><fpage>e14</fpage><lpage>e14</lpage><permissions><copyright-statement>&#x000a9; 2012 by the American Diabetes Association.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="e14.pdf"/></article-meta></front><body><p>We thank Tobar et al. (<xref ref-type="bibr" rid="B1">1</xref>) for sharing the brief results and conclusions of an elegant study in an animal model of obesity and type 2 diabetes that allowed confirmation of the antihyperglycemic effect of diacerein, a medication frequently used in the treatment of rheumatic diseases, and the responsible mechanisms by which diacerein was able to reduce the chronic subclinical inflammation at the cellular level in liver, muscle, and adipose tissue with improvement of glucose metabolism, inducing a reduction in hepatic glucose output. Contrary to those findings, in our study in drug-na&#x000ef;ve patients with type 2 diabetes (<xref ref-type="bibr" rid="B2">2</xref>), insulin sensitivity was not improved, interleukin-6 levels were not significantly decreased, and diminution of triglycerides concentration was limited with diacerein administration. This may be due to differences in the inflammatory behavior between the studied models (animal and human) or to insufficient treatment duration, or may be, as was commented by Tobar et al., because hepatic glucose output was not measured, and this is an important evaluation. In any case, the above-mentioned limitations allow justification of other investigations under different conditions, independent of the beneficial effect on insulin secretion reported in our article that may support the potential use of diacerein in the treatment of patients with type 2 diabetes.</p></body><back><ack><title>Acknowledgments</title><p>No potential conflicts of interest relevant to this article were reported.</p><p>The authors thank Sharon Morey, Executive Editor, Scientific Communications, for English editorial assistance.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobar</surname><given-names>N</given-names></name><name><surname>Oliveira</surname><given-names>AG</given-names></name><name><surname>Guadagnini</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Comment on: Ramos-Zavala et al. Effect of diacerein on insulin secretion and metabolic control in drug-na&#x000ef;ve patients with type 2 diabetes: a randomized clinical trial</article-title>. <source>Diabetes Care</source> <year>2011</year>;<volume>34</volume>:<fpage>1591</fpage>&#x02013;<lpage>1594</lpage> <comment>(Letter). Diabetes Care 2012;35:e13. DOI: 10.2337/dc11-1856</comment><pub-id pub-id-type="pmid">21610123</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Zavala</surname><given-names>MG</given-names></name><name><surname>Gonz&#x000e1;lez-Ortiz</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;nez-Abundis</surname><given-names>E</given-names></name><name><surname>Robles-Cervantes</surname><given-names>JA</given-names></name><name><surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname><given-names>R</given-names></name><name><surname>Santiago-Hern&#x000e1;ndez</surname><given-names>NJ</given-names></name></person-group> <article-title>Effect of diacerein on insulin secretion and metabolic control in drug-na&#x000ef;ve patients with type 2 diabetes: a randomized clinical trial</article-title>. <source>Diabetes Care</source> <year>2011</year>;<volume>34</volume>:<fpage>1591</fpage>&#x02013;<lpage>1594</lpage><pub-id pub-id-type="pmid">21610123</pub-id></mixed-citation></ref></ref-list></back></article>